Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term behavioral symptom clusters among survivors of early-stage breast cancer. development and validation of a predictive model.
Pagliuca M, Havas J, Thomas E, Drouet Y, Soldato D, Franzoi MA, Ribeiro J, Chiodi CK, Gillanders E, Pistilli B, Menvielle G, Joly F, Lerebours F, Rigal O, Petit T, Giacchetti S, Dalenc F, Wassermann J, Arsene O, Martin AL, Everhard S, Tredan O, Boyault S, De Laurentiis M, Viari A, Deleuze JF, Bertaut A, André F, Vaz-Luis I, Di Meglio A. Pagliuca M, et al. Among authors: de laurentiis m. J Natl Cancer Inst. 2024 Sep 9:djae222. doi: 10.1093/jnci/djae222. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39250750
Corrigendum to "Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)" [Cancer Treatment Reviews 123 (2024) 102672].
Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Dri A, et al. Among authors: de laurentiis m. Cancer Treat Rev. 2024 Apr;125:102714. doi: 10.1016/j.ctrv.2024.102714. Epub 2024 Mar 16. Cancer Treat Rev. 2024. PMID: 38493647 No abstract available.
Pharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells.
Costa A, Forte IM, Pentimalli F, Iannuzzi CA, Alfano L, Capone F, Camerlingo R, Calabrese A, von Arx C, Benot Dominguez R, Quintiliani M, De Laurentiis M, Morrione A, Giordano A. Costa A, et al. Among authors: de laurentiis m. Front Oncol. 2024 Jul 1;14:1418951. doi: 10.3389/fonc.2024.1418951. eCollection 2024. Front Oncol. 2024. PMID: 39011477 Free PMC article.
Neuropsychological tests at the Italian Centers for Cognitive Disorders and Dementias: results from a survey on 450 specialized services.
Vaccaro R, Lorenzini P, Giaquinto F, Matascioli F, Carnevale G, Sciancalepore F, Gasparini M, Salvi E, Corbo M, Locuratolo N, Vanacore N, Bacigalupo I; Permanent Table of the National Dementia Plan Study Group; CCDDs Study Group. Vaccaro R, et al. Aging Clin Exp Res. 2024 Dec 20;37(1):1. doi: 10.1007/s40520-024-02869-6. Aging Clin Exp Res. 2024. PMID: 39704981 Free PMC article.
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer.
Cucciniello L, Blondeaux E, Bighin C, Gasparro S, Russo S, Dri A, Pugliese P, Fontana A, Cortesi E, Ferzi A, Riccardi F, Sini V, Boni L, Fabi A, Montemurro F, De Laurentiis M, Arpino G, Del Mastro L, Gerratana L, Puglisi F. Cucciniello L, et al. Among authors: de laurentiis m. NPJ Breast Cancer. 2024 Dec 18;10(1):105. doi: 10.1038/s41523-024-00713-8. NPJ Breast Cancer. 2024. PMID: 39695115 Free PMC article.
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gión M, Guarneri V, Bianchini G, Wildiers H, Escrivá-de-Romaní S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Harbeck N, et al. Nat Med. 2024 Dec;30(12):3780. doi: 10.1038/s41591-024-03349-0. Nat Med. 2024. PMID: 39653780 Free PMC article. No abstract available.
Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions.
Caltavituro A, Buonaiuto R, Salomone F, Pecoraro G, Martorana F, Lauro VD, Barchiesi G, Puglisi F, Del Mastro L, Montemurro F, Giuliano M, Arpino G, De Laurentiis M. Caltavituro A, et al. Among authors: de laurentiis m. Crit Rev Oncol Hematol. 2024 Nov 28;206:104577. doi: 10.1016/j.critrevonc.2024.104577. Online ahead of print. Crit Rev Oncol Hematol. 2024. PMID: 39613237 Review.
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis.
Buonaiuto R, Caltavituro A, Tafuro M, Longobardi A, Pavone G, De Santis P, Caputo R, De Angelis C, Del Mastro L, Puglisi F, Giuliano M, Arpino G, Pagliuca M, De Laurentiis M. Buonaiuto R, et al. Among authors: de laurentiis m. Breast. 2024 Nov 4;79:103833. doi: 10.1016/j.breast.2024.103833. Online ahead of print. Breast. 2024. PMID: 39579620 Free PMC article. Review.
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study.
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L. Molinelli C, et al. Among authors: de laurentiis m. Eur J Cancer. 2024 Dec;213:115113. doi: 10.1016/j.ejca.2024.115113. Epub 2024 Nov 4. Eur J Cancer. 2024. PMID: 39536433 Free article.
275 results